Jazz Pharmaceuticals plc
Jazz Pharmaceuticals Extends and Increases Revolving Credit Facility
Summary
On November 26, 2024, Jazz Pharmaceuticals plc amended its Credit Agreement to increase the initial revolving credit facility from $500 million to $885 million and extend the maturity date from May 5, 2026, to November 26, 2029, subject to certain conditions. The interest rate margin was also reduced and the applicable margin will now range from 1.75% to 2.75% (for Term SOFR borrowings) and 0.75% to 1.75% (for prime lending rate borrowings). The amendment also includes financial covenants related to the Company's leverage and interest coverage ratios.
Profitelligence Alerts
Get alerts for JAZZ
Be first to know when Jazz Pharmaceuticals plc files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.
Official SEC Documents
Advertisement